SK Biopharmaceuticals Co Ltd
KRX:326030

Watchlist Manager
SK Biopharmaceuticals Co Ltd Logo
SK Biopharmaceuticals Co Ltd
KRX:326030
Watchlist
Price: 89 600 KRW Market Closed
Updated: May 19, 2024
Section:
 

Wall Street
Price Targets

Price Targets Summary
SK Biopharmaceuticals Co Ltd

Wall Street analysts forecast SK Biopharmaceuticals Co Ltd stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for SK Biopharmaceuticals Co Ltd is 111 656 KRW with a low forecast of 51 510 KRW and a high forecast of 136 500 KRW.

Lowest Forecast
Wall Street Target
51 510 KRW
43% Downside
Average Forecast
Wall Street Target
111 656 KRW
25% Upside
Highest Forecast
Wall Street Target
136 500 KRW
52% Upside
Lowest
Price Target
51 510 KRW
43% Downside
Average
Price Target
111 656 KRW
25% Upside
Highest
Price Target
136 500 KRW
52% Upside
SK Biopharmaceuticals Co Ltd Competitors:
Price Targets
950
Lee's Pharmaceutical Holdings Ltd
11% Downside
603998
Hunan Fangsheng Pharmaceutical Co Ltd
13% Downside
Y
002019
Yifan Pharmaceutical Co Ltd
18% Upside
K
KOTRA
Kotra Industries Bhd
20% Upside
950
Lee's Pharmaceutical Holdings Ltd
11% Downside
603998
Hunan Fangsheng Pharmaceutical Co Ltd
13% Downside
Y
002019
Yifan Pharmaceutical Co Ltd
18% Upside
K
KOTRA
Kotra Industries Bhd
20% Upside
R
000650
Renhe Pharmacy Co Ltd
87% Upside
DRREDDY
Dr Reddy's Laboratories Ltd
4% Upside
002773
Chengdu Kanghong Pharmaceutical Group Co Ltd
6% Upside
234080
JW Life Science Corp
47% Upside

Revenue
Forecast

Revenue Estimate
SK Biopharmaceuticals Co Ltd

For the last 5 years the compound annual growth rate for SK Biopharmaceuticals Co Ltd's revenue is 218%. The projected CAGR for the next 3 years is 35%.

218%
Past Growth
35%
Estimated Growth
Estimates Accuracy
1%
Average Beat
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
SK Biopharmaceuticals Co Ltd

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
10%
Average Beat
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
SK Biopharmaceuticals Co Ltd

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
3%
Average Beat
What are analyst estimates?

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is SK Biopharmaceuticals Co Ltd's stock price target?
Price Target
111 656 KRW

According to Wall Street analysts, the average 1-year price target for SK Biopharmaceuticals Co Ltd is 111 656 KRW with a low forecast of 51 510 KRW and a high forecast of 136 500 KRW.

What is SK Biopharmaceuticals Co Ltd's Revenue forecast?
Projected CAGR
35%

For the last 5 years the compound annual growth rate for SK Biopharmaceuticals Co Ltd's revenue is 218%. The projected CAGR for the next 3 years is 35%.

ALPHA SPREAD
Join more than 138,400+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.